|
- ENJAYMO® (sutimlimab-jome) | Cold Agglutinin Disease Treatment
ENJAYMO is the first and only FDA-approved treatment for people with cold agglutinin disease (CAD) to help decrease the need for red blood cell transfusion
- ENJAYMO® (sutimlimab-jome) | What is ENJAYMO?
ENJAYMO is a chemotherapy-free treatment proven to help stop the destruction of red blood cells (hemolysis) in cold agglutinin disease (CAD)
- ENJAYMO® (sutimlimab-jome) | Patient Solutions
ENJAYMO Patient Solutions is here to help you with disease and treatment education as well as financial assistance for eligible patients
- ENJAYMO® (sutimlimab-jome) | How ENJAYMO Can Help Treat CAD
ENJAYMO is a chemotherapy-free treatment option that helps stop hemolysis in its tracks What Happens in people living with CAD When you have Cold Agglutinin Disease (CAD), your immune system makes cold agglutinin antibodies that mistake red blood cells as a threat to the body When the antibodies come close to a red blood cell, they attach
- ENJAYMO® (sutimlimab-jome) | FAQ
ENJAYMO may lower the ability of your immune system to fight infections ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B
- ENJAYMO is the first and only FDA-approved treatment for people with . . .
ENJAYMO is the first and only FDA-approved treatment for people with Cold Agglutinin Disease (CAD) INDICATION ENJAYMO® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD) It is not known if ENJAYMO is safe and effective in children
- ENJAYMO® (sutimlimab-jome) | ENJAYMO Dosing
The ENJAYMO dosing schedule is designed to provide a continuous level of medicine ENJAYMO is given as an intravenous (IV) infusion weekly for the first 2 weeks, and then every 2 weeks thereafter
- HIGHLIGHTS OF PRESCRIBING INFORMATION - enjaymo. com
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENJAYMO safely and effectively See full prescribing information for ENJAYMO ENJAYMO® (sutimlimab-jome) injection, for intravenous use Initial U S Approval: 2022
|
|
|